OBJECTIVES: To determine recurrent (infective) exacerbations (AECOPD) and health care utilization among patients with moderate to very severe COPD.

METHODS: Data for this study was obtained from the PHARMO Record Linkage System (RLS), which includes drug dispensing records from pharmacies, hospitalization records and detailed information from general practitioners. Patients with moderate to very severe COPD (GOLD II-III-IV) and a moderate or severe AECOPD between 2000 and 2010 were included in the study. Moderate and severe COPD were defined by smoking history and hospitalization respectively. Date of first AECOPD after first GOLD classification-test was defined as cohort entry. Study patients were followed from cohort entry to end of registration in PHARMO RLS, death, or end of study period, whichever occurred first. During follow-up, all recurrent AECOPDs were counted and characterized by type of AECOPD and health care utilization.

RESULTS: Of patients included in the study, 56% was male and mean (±SD) age was 66 (±11) years. The proportion of patients with GOLD II, III and IV was 52%, 34% and 14% respectively. At cohort entry, 747 patients (84%) had a moderate AECOPD and 139 (16%) had a severe AECOPD. The overall exacerbation recurrence rate per person year (PY) was 0.9. When stratifying by GOLD stage at cohort entry, this rate increased from 0.6 for patients with GOLD II to 1.1 for GOLD III patients and 1.3 for GOLD IV patients. The rate of severe exacerbations was 0.1 for patients with GOLD II and III and 0.2 for patients with GOLD IV. Mean hospital stay for severe exacerbations was 12 (±11) days and 75% were infectious. Moderate exacerbations were mostly treated with tetracyclines (46%), followed by penicillins (34%).

CONCLUSIONS: Moderate exacerbations were most prevalent in the highest income and education groups as well as in West Germany. Medical treatment of acute symptoms was reported by 21% of the respondents. Regarding allergy perception, 39% appraised allergies as “easily treatable”; this opinion was more prevalent in women and in privately insured persons. In an open question on potential allergy triggers environmental factors were mentioned most often (26%), chemical agents.

PRES 11 THE SHORT-TERM ECONOMIC IMPACT OF THREE CHILDHOOD PREVENTIVE HEALTH PROGRAMS IN ISRAEL

Kirsch F1, Wenig C1, Menn P2, Leidl R1
1University Clinics of Hamburg, UKE, Hamburg, Germany, 2Hautklinik Klinikum, Minden, Germany

OBJECTIVES: To estimate the budget impacts of immunization against pneumococcal disease (PD) and human papillomavirus (HPV), and of prophylaxis against severe respiratory syncytial virus (RSV) disease, in Israel. METHODS: Incidence-based models compared the annual budget impact, from the Israeli health care system perspective, of the PD and RSV programs. Because HPV disease is slow developing, cumulative five-year and seven-year discounted costs were included for the HPV program. Model inputs were from published literature. Outputs included total program cost, disease costs and disease cost offsets, in 2012 Israeli New Shekels (NIS). RESULTS: A 13-valent pneumococcal conjugate vaccine (PCV13) vaccination program, covering 175,488 infants, prevented approximately 78 cases of invasive disease, 218 of pneumococcal pneumonia and 225 of pneumococcal otitis media. Immunization against HPV in a year’s cohort of 66,182 twelve-year old girls prevented approximately 321 cases of cervical intraepithelial neoplasia and 48 cases of genital warts over five years. RSV prophylaxis in 2,266 high-risk infants prevented approximatley 138 hospitalizations for severe RSV disease. Total disease costs in year one of the model, without the programs, were 7,250,461 NIS (PD) and 17,988,932 (RSV infection); cumulative five-year disease costs in the HPV model without immunization were 7,931,131.NIS. Total disease costs, with the programs (excluding the cost of prophylaxis) were 3,305,522 NIS (PD) and 14,426,876 NIS (RSV disease), for annual savings of 3,944,939 NIS and 3,562,056 NIS, respectively. HPV disease costs over five years with the program were 353,480 NIS, saving an estimated 795,713 NIS over five years. The immunization programs cost: 133,135,790 NIS (PD), 35,106,399 NIS (PCV13), and 34,886,624 NIS (HPV). CONCLUSIONS: All programs had substantial acquisition costs, but annual net savings, when the costs of the program were excluded. Even programs considered expensive are well-positioned financially within the context of other childhood preventive health strategies, when compared to appropriate populations.

PRES 13 VARIATION OF COST OF CHRONIC OBSTRUCTIVE LUNG DISEASE IN ADULTS IN GERMANY: A SYSTEMATIC REVIEW

Kirsch F, Wenig C, Menn P, Leidl R

University Maximilians-University Munich, Munich, Germany, Helmholtz Zentrum München - German Research Center for Environmental Health, Munich, Germany

OBJECTIVES: A significant economic burden for society is linked to chronic obstructive lung diseases because of their high and still growing epidemiologic impact worldwide. The purpose of this systematic review is to estimate the cost-of-illness per case for the two most important obstructive lung diseases, asthma and COPD, for adults in Germany. METHODS: A systematic search of Pubmed, Embase, EconLit and Business Source Complete was performed for the years 1995 to 2012 in order to identify German cost-of-illness studies for asthma and COPD. Studies identified were analysed according to methods used, and cost findings were inflated to 2010 prices and compared within the same disease. RESULTS: Six studies for asthma, seven for COPD and one for both diseases met the inclusion criteria. The costs for asthma differ widely, ranging from minimum to maximum by a factor of 6.7 for direct costs and 9.6 for indirect costs per case. For COPD, costs per case ranged by a factor of 4.2 for direct costs and of 6.5 for indirect costs. In spite of the heterogeneity in methodology and results, medication could be identified as the most important component of direct costs and work loss as the most important component of indirect costs. All in all, the estimated costs per case of illness and year varied by a factor of 5.7 with a maximum slightly above 2,500 € for asthma and by a factor of 2.9 with a maximum of almost 3,500 € for COPD. CONCLUSIONS: Findings confirm that asthma and COPD are costly but results vary markedly. COPD causes both higher costs per case and higher total costs as a result of its higher prevalence. Results emphasize the economic relevance of effective prevention and disease management for these chronic obstructive lung diseases.

PRES 14 CLINICAL AND PHARMACOECONOMIC ASPECTS OF ALLERGEN IMMUNOTHERAPY IN THE SLOVAK REPUBLIC

Biele F1, Pruinec P2, Toro P3
1Trencin University, Trencin, Slovak Republic, 2University Hospital, Bratislava, Slovak Republic, 3Stalagezus ZR, Bratislava, Slovak Republic

OBJECTIVES: To evaluate direct costs of allergen immunotherapy with regard to its clinical benefit in the treatment of allergic rhinitis in the Slovak Republic. METHODS: In co-operation with the General Insurance Health Company, the largest insurer in Slovakia covering approximately 66% of all patients, the clinical benefit was analyzed with direct medical costs (costs of illness) on the one hand, minimizing and prevention of onset of asthma bronchiale (AB), in a short- and long-term period. The outcomes were obtained from an analysis of a group of 109,974 patients who were newly diagnosed with allergic rhinitis (AR) in 2002 and were followed up until the end of 2009 in the total population. Allergic rhinitis was detected in only 17,442 of these 72 patients. RESULTS: The prevalence of AR and AB was 9.34% and 4.74%, respectively. In 2010, the total direct costs of AR and AB in Slovakia were approx. 37,946,000 € and 51,512,000 €, respectively. Direct medical costs of AR and AB treatment in the evaluated group were 50,144 € and 198,035 €, respectively. Allergen immunotherapy decreases average annual costs of pharmacotherapy of AR by 17 € per patient and annual costs of prevention of onset of AB by 164.89 € per